Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 7257

Next Previous
Drug Profile

REGN 7257

Alternative Names: REGN-7257

Latest Information Update: 17 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin receptor common gamma subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Aplastic anaemia
  • Preclinical Graft-versus-host disease

Most Recent Events

  • 06 Dec 2025 Safety and pharmacokinetics data from a phase I/II trial in Aplastic anaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition, 2025 (ASH-Hem-2025)
  • 20 Dec 2024 Regeneron Pharmaceuticals suspends a phase I/II trial in Aplastic anaemia (Treatment-experienced) in the US, France, South Korea and the United Kingdom (IV) (NCT04409080)
  • 10 Dec 2022 Pharmacodynamics data from preclinical studies in Graft-versus-host disease and Aplastic anaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top